Cervix News and Research

RSS

Yashoda Cancer Institute in India to expand use of Varian Medical Systems' RapidArc radiotherapy

A hospital that is using RapidArc radiotherapy to treat cancers of the head & neck and cervix is announcing it will be expanding its use for treatment of other cancers. Yashoda Cancer Institute in Hyderabad has found it can deliver image-guided, intensity modulated radiotherapy (IMRT) faster and more precisely using the RapidArc technology from Varian Medical Systems.

19 Oct 2009

NCCN updates NCCN Clinical Practice Guidelines in Oncology for Cervical Cancer Screening

The National Comprehensive Cancer Network (NCCN) recently made updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Cervical Cancer Screening that include a new section providing recommendations for women who have positive results for the HPV High Risk DNA test but negative cervical cytology screen/Pap smears.

15 Oct 2009

Vaccination against HPV will help decrease cervical cancer death rate in India

Although a wide spectrum of human papillomavirus is seen across the population of India, HPV-16 and HPV-18 are the most common types and a vaccination targeting these types could eliminate 75 percent of the cervical cancers in the region, according to data presented at the American Association for Cancer Research Frontiers in Basic Cancer Research Meeting.

12 Oct 2009

Spectrascience receives Japanese patent for its Optical Biopsy Forceps System and Method of Sampling Tissue

SpectraScience, Inc., a San Diego based medical device company, today announced that it has been awarded Japanese Patent number 4361683 for its Optical Biopsy Forceps System and Method of Sampling Tissue.

8 Oct 2009

mtm laboratories signs additional tranche of Euro 7 million to its Series C funding

mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company’s last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in equity.

6 Oct 2009

Guided Therapeutics awarded $2.5M NCI grant for marketing LightTouch technology

Guided Therapeutics, Inc. today announced that it was awarded a $2.5 million matching grant by the National Cancer Institute (NCI) to bring to market and expand the array features for its LightTouch™ non-invasive cervical cancer detection technology. The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.

6 Oct 2009

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.

3 Oct 2009

Advaxis announces Phase I trial results of its ADXS11-001 therapeutic cancer vaccine

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection.

1 Oct 2009

HPV screening and vaccination programmes could eradicate cervical cancer

Cervical cancer could be eradicated within the next 50 years if countries implement national screening programmes based on detection of the human papilloma virus (HPV), which causes the disease, together with vaccination programmes against the virus, according to a cervical cancer screening expert.

24 Sep 2009

Mayo Clinic Women's HealthSource discusses myths and facts about ovarian cancer

But not all the news about ovarian cancer is grim. Incidence is declining. Doctors are learning more about early symptoms and more effective treatments. The September issue of Mayo Clinic Women's HealthSource looks at myths and facts about ovarian cancer.

17 Sep 2009

FDA provides PMA approval for Spectrascience's WavSTAT technology enhancements

SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that its application for premarket approval (PMA) relating to key enhancements of its WavSTAT platform technology has been approved by the Food and Drug Administration. The Company can now begin commercial distribution of the enhanced WavSTAT technology.

17 Sep 2009

Hispanic/Latino Americans have a unique cancer risk profile, says report

The latest edition of Cancer Facts & Figures for Hispanics/Latinos reports that Hispanic/Latino Americans -the largest, fastest-growing, and youngest minority in the United States-have a unique cancer risk profile that requires a targeted approach to cancer prevention.

15 Sep 2009

Oral and throat cancers linked to human papilloma virus

Infection by the human papilloma virus (HPV), the most common sexually transmitted disease, has been linked to more than one third of all oral and throat cancers according to Dr. Solomon Hamburg, president of the prestigious Tower Cancer Research Foundation.

10 Sep 2009

Presence of virus linked with malignant human prostate cancer cells

In a finding with potentially major implications for identifying a viral cause of prostate cancer, researchers at the University of Utah and Columbia University medical schools have reported that a type of virus known to cause leukemia and sarcomas in animals has been found for the first time in malignant human prostate cancer cells.

7 Sep 2009

Vaccinating women against HPV prevents breast cancer

Vaccinating women against the human papillomavirus (HPV) may prevent some forms of breast cancer and save tens of thousands of lives each year, new Australian research suggests.

4 Sep 2009

Varian Medical Systems unveils first low-energy radiotherapy system with image-guidance and RapidArc treatment capabilities

Varian Medical Systems is introducing the world's first low-energy radiotherapy system with image-guidance and RapidArc treatment capabilities for international cancer clinics. Varian's UNIQUE(TM) radiotherapy system is expected to make advanced care more affordable and more widely available to cancer patients around the world.

31 Aug 2009

Low income women less likely to be screened for cancer in Ontario

Less than half of Ontario women with abnormal Pap tests receive recommended and potentially life-saving follow-up care, according to a new women's health study by researchers at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES). What's more, low-income women are less likely to be screened for cancer compared to their high-income counterparts.

20 Aug 2009

Current diagnostic tests for ovarian cancer woefully ineffective

A new study finds that in order to make a significant dent in the mortality rate for the deadly cancer, the tests would have to be able to detect tumors of less than 1 cm in diameter, or about 200-times smaller in mass than those currently used to assess potential new tests. Still, if that hurdle can be overcome, there is good reason to believe that testing could make a big difference: The window of opportunity for treating these clinically undetectable cancers before they become life threatening is surprisingly long: about four years.

28 Jul 2009

Magnetic resonance imaging accurately depicts deep endometriosis

Using magnetic resonance imaging (MRI), radiologists may be able to diagnose deep endometriosis and accurately locate lesions prior to surgery, according to a new study published in the online edition of Radiology.

7 Jul 2009

HPV testing for cervical screening investigated

New research, published in The Lancet Oncology, has found that combining human papillomavirus (HPV) testing with routine liquid-based cytology (LBC) screening does not increase the detection of cervical cancer compared with LBC screening alone. The trial funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme aimed to determine whether testing for HPV in the cervix might increase the effectiveness of the cervical screening programme.

25 Jun 2009